According to the Zhitong Finance APP, Remegen (09995) rose more than 4% in midday trading. As of the time of publication, it has risen by 3.45%, to HKD 27, with a turnover of HKD 18.1935 million.

In terms of news, on June 13, Remegen announced that the Phase III clinical trial of Vedolizumab (trade name: Entyvio) for the treatment of HER2-positive advanced breast cancer with liver metastases achieved positive results in the primary endpoint. The company plans to submit a listing application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in the near future. It is reported that in 2023, the sales volume of Remegen's injection of Vedolizumab was 173,700 units, an increase of 15.24% year-on-year.